They have $152M in cash as of end of Q1, they have a $75M credit line, and they will quite likely receive a milestone from BMY ($80M? I forget). They also may well get a EU Reco milestone payment.
Please tell me how the balance sheet is that weak?
Yes, as with any bio if all the tech fails then so will the company. But the winter deadline seams a tad irrational.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.